|
|
||||||||
J Thorac Cardiovasc Surg 1994;108:987-988
© 1994 Mosby, Inc.
LETTERS TO THE EDITOR |
Division of Cardiac Surgery
Children's Hospital and Medical Center
Division of Cardiothoracic Surgery
Department of Surgery
University of Washington Medical Center
Seattle, WA 98105
Reply to the Editor:
On behalf of our coauthors, we would like to express our appreciation to Dr. Mohan and his associates for their interest in our work.
1 Dr. Mohan is correct that we did not demonstrate how well endothelium can bepreserved in the experimental setting. Instead, we attempted to define how well it ispreserved in our usual clinical practice.
We believe that Yankah and associates did demonstrate viability of endothelial cells on cryopreserved allografts. Yankah's use of alcian blue exclusion, although not without its limitations, is recognized as a useful marker of cell viability.
2 Yankah and colleagues
3,4 did not use anti-factor VIII staining to confirm these cells as endothelium. However, using the same method of cell harvesting used by Yankah's group, we observed that most of these cells are in fact endothelium in both human
1 and animal tissues.
5 Factor VIII staining may actually be an inappropriate method for identifying human cardiac valve endothelium.
6
Dr. Mohan and his colleagues are to be congratulated for cryopreserving porcine valves in a fashion that results in both morphologic integrity and persistence of in vitro function.
7 These techniques may indeed result in superior graft longevity. However, we question Dr. Mohan's statement, "Cryopreservation must aim to preserve a viable endothelial lining . . . ." A viable endothelial lining may result in a stronger host immune response, as pointed out by us in our article and by Dr. Mohan's group in their earlier work.
7 Such a host response may actually reduce graft longevity.
We also question Dr. Mohan's assertion that "a lack of viable endothelium" suggests that "preservation of the remaining valve may also then be suspect." This statement contradicts Dr. Mohan's previous publication, which states that "a procedure which allows better preservation of endothelial viability may or may not lead to better fibroblast survival."
7 As shown by van der Kampand associates,
8 whom Dr. Mohan cites, fibroblasts and endothelium do not necessarily demonstrate a parallel response to preservation techniques.
Again, we thank Dr. Mohan and associates for their thoughtful analysis of our paper. We look forward to their continued basic investigations and eventual clinical trials in this area.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |